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ABSTRACT 
Nasopharyngeal carcinoma (NPC) shows broad differences in racial and 
geographical distribution, radiosensitivity, and a multifactorial etiology. This thesis 
aims to identify molecular biomarkers with potentially valuable for prognostic 
implications in NPC.  
This thesis involved a series of studies which were performed on cohorts of 
patients with NPC to investigate the genetic alterations, Epstein-Barr virus (EBV) 
infection, and gene expression profiles, and to assess their correlations with 
clinicopathological parameters and survival of NPC patients. The results indicated that 
overexpression of caveolin-1 (Cav-1) and extracellular matrix metalloproteinase 
inducer (EMMPRIN/CD147) in NPC were significantly associated with TNM stage, 
metastasis, and poor prognosis (Paper I). Loss of heterozygosity (LOH) on 9p21, 16q 
and 19q13 may be responsible for tumor aggression behavior and progression of NPC, 
with a possible interaction between allelic loss and EBV infection in the etiology of 
NPC (Paper II). EBV latent membrane protein (LMP) 1 overexpression was 
significantly correlated with p53 accumulation in NPC, CD8+ T cell infiltration, and 
matrix metalloproteinase (MMP) 9 overexpression in NPC cells. Moreover, plasma 
EBV DNA was detectable at a high frequency in primary NPC (96%). Higher plasma 
EBV-DNA levels were positively correlated with advanced TNM stages, lymph node 
metastasis, and NPC relapses (Papers III-V). Overexpression of LMP1 regulated the 
mTOR signaling pathway in NPC, possibly through phosphorylation of 
AKT/mammalian target of rapamycin (mTOR)/phospho-P70S6 kinase 
(P70S6K)/4EBP1. LMP1 expression was closely correlated with expression of p-
mTOR, p-P70S6K and p-4EBP1 in NPC tumors, while expression levels of p-P70S6K, 
p-4EBP1 and LMP1 were significantly correlated with overall survival in NPC patients 
(Paper V).  
Paper VI presents a new molecular NPC-space vector modulation (SVM) 
classifier, which integrates sex and seven genes, including LMP1, CD147, Cav-1, p-
P70S6K, MMP11, survivin, and secreted protein acidic and rich in cysteine (SPARC). 
This NPC-SVM classifier could refine the classification of NPC patients into high- and 
low-risk groups, which demonstrated significant differences in 5-year disease-specific 
survival (DSS) rates in a group of 411 validation patients (86.2% vs. 37.6%, p<0.001). 
Paper VII presents a new histological classification study, which was developed mainly 
on the basis of morphological characteristics and tumor cell differentiation. Of 3,839 
tumors, 2,057 (53.6%) were histologically classified as undifferentiated epithelial cell 
carcinoma (UECC), 942 (24.5%) as undifferentiated mixed epithelial-sarcomatoid cell 
carcinoma (UESCC), 640 (16.7%) as undifferentiated sarcomatoid cell carcinoma 
(USCC), and 200 (5.2%) as squamous cell carcinoma (SCC). Based on the new 
histological classification system, the 5-year DSS rates were 76.4% for UECC, 66.0% 
for UESCC, 56.0% for USCC, and 32.7% for SCC. Stratified according to the new 
classification, patients with UECC and UESCC who received radiochemotherapy (RCT) 
showed better 5-year DSS rates than those who received radiotherapy (RT) alone. 
In summary, the results of these studies indicate that LOH, differentially-
expressed genes, and EBV markers can act as prognostic biomarkers in NPC patients. 
The NPC-SVM classifier and the new proposed histopathological classification provide 
better discriminative prediction of NPC prognosis than the current WHO classification, 
as well as a means of monitoring the therapeutic efficacy of RCT and RT in advanced-
stage NPC patients.  
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INTRODUCTION 
 
Epidemiology and etiology of nasopharyngeal carcinoma 
Nasopharyngeal carcinoma (NPC) shows broad differences in racial and geographical 
distribution, radiosensitivity, and a multifactorial etiology (Feng et al, 2002; Henderson 
et al, 1976; Lin et al, 2004). NPC is a common malignancy in areas of the 
Mediterranean, Central Africa, Southeast Asia, and Southern China, with an incidence 
rate of 25–40 per 100,000 persons per year among the Southern Chinese especially 
those of Cantonese origin (Licitra et al, 2003; Titcomb, 2001). In contrast, NPC has an 
incidence of well under 1 per 100,000 persons per year in Caucasians from North 
America and other Western countries. In the year 2000, a total of 64,798 new cases 
were registered worldwide, and more than 80% of those were reported from China, 
Southeast Asia, and other Asian countries (Ferlay, 2001).  Southern Chinese 
immigrants also have a higher risk of NPC compared to the local Western population. 
Independent of race/ethnicity, men are 2- to 3-fold more frequently affected than 
women (Yu & Yuan, 2002). However, recent changes in the epidemiology of NPC are 
reflected by a decreasing incidences of NPC (around 30%) in Hong Kong over the past 
20 years (Lee et al, 2003), possibly related to changes in environmental factors. The 
dramatic differences in the incidence of NPC among populations and geographic areas 
are shown in Figures 1 and Figures 2. 
 
Figure 1. Differences in the incidences of NPC worldwide.  Modified from IARC：
GLOBOCAN, 2008 
- 2 - 
   
 
Figure 2. High incidence of NPC in Southern China. Modified from “Atlas of Cancer 
Mortality in the Peoples Republic of China (1973-1976). Beijing, China Map Press, 
Pages 81-82 (1979)  
 
Epstein-Barr virus infection and NPC 
Epstein-Barr virus, EBV, which ubiquitously infects more than 90% of the world’s 
population, was the first human tumor virus identified to be causally associated with 
various lymphoid and epithelium malignancies (Epstein et al, 1966; Young & Murray, 
2003). The association between EBV infection and NPC is well documented, and the 
EBV genome is presented in virtually all NPC cells. The underlying mechanism 
whereby EBV infects normal healthy carriers is summarized in Figure 3. After primary 
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infection at an early age, persistent latent EBV infection is found in some resting B 
cells, but has not been detected in the nasopharyngeal epithelia (NPE) in healthy 
individuals (Babcock et al, 1998; Tao et al, 1995). However, EBV infection has been 
demonstrated in in situ carcinomas of the nasopharynx, which are presumed to be 
precursor lesions of NPC (Niedobitek et al, 1996). These findings suggest that EBV 
infection occurs before invasive growth begins, but probably does not represent the first 
step in the pathogenesis of NPC.  
 
Figure 3. EBV infection in normal healthy virus carriers. Modified from: Expert 
Reviews in Molecular Medicine(Young, 2001).  
 
NPC, particularly the undifferentiated type, is the most commonly known EBV-
associated cancer (Young & Murray, 2003) and four EBV latent proteins can be 
expressed in these tumors (Andersson-Anvret et al, 1979; Lo et al, 2004). BARF 1 and 
the three latent membrane proteins (LMPs 1, 2A, 2B). EBNA-LP is transcribed from 
variable numbers of repetitive exons. EBNA1, the primary role of which is to enable 
replication of the viral episomal genome (Yates et al, 1985), is the most widely-
expressed protein in NPC. LMP2A and LMP2B are composed of multiple exons 
located on either side of the terminal repeat region, which is formed during the 
circularization of the linear DNA to produce the viral episome. Although both LMP1 
and LMP2A are detectable in NPC samples, most recent research has focused on LMP1 
because of its known oncogenic properties in B cells (Hung et al, 2001; Thorley-
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Lawson, 2001). However, LMP2A has also been detected in more than 95% of NPC 
samples at the mRNA level, and in about 50% of these specimens at the protein level, 
whereas LMP1 could be detected in only about 65% and 35% of NPC samples at the 
mRNA or protein levels, respectively (Busson et al, 1992; Chen et al, 1995; Heussinger 
et al, 2004; Niedobitek et al, 1992; Young et al, 1988). In addition, one study found 
that high levels of LMP2A expression in NPC samples were correlated with a poor 
survival outcome, although this study was carried out using only a small cohort (Pegtel 
et al, 2005). EBER1 and EBER2 are highly-transcribed non-polyadenylated RNAs, and 
their transcription is a consistent feature of latent EBV infection. A pivotal biologic 
property of the virus is its ability to alter B-lymphocyte growth in vitro, leading to 
permanent growth transformation. 
 
Although LMP1 was demonstrated in all examined premalignant in situ lesions by 
immunostaining in and is thought to precede NPC (Pathmanathan et al, 1995; 
Permeen et al, 1990), only 35–65% of NPCs were LMP1-positive by 
immunoblotting, while up to 90% were positive by sensitive PCR (Chen et al, 
1995). We previously demonstrated that LMP1 status affected clinical outcome in 
terms of tumor growth, therapy response, invasiveness, and risk of recurrence. 
Clinical and follow-up data from 74 NPC patients showed that LMP1-postive 
NPCs grow faster and more expansively than LMP1-negative tumors (Hu et al, 
1995). To further elucidate the impact of LMP1 on the natural history of NPC, we 
examined markers related to tumor cell proliferation, apoptosis, leukocyte 
infiltration, and metastasis in NPC biopsies, in relation to LMP1 status. 
 
Genetic alterations in NPC 
The distinct geographic variations in the incidence of NPC indicate genetic and/or 
environmental contributions to its development. In support of the influence of genetic 
factors, Southern Chinese are an ethnically-distinct population that may be related to 
Aleutean Indians, another ethnically distinct, (middle) high-risk group. Possible 
environmental or cultural factors include the ingestion of Cantonese-style salted fish, 
especially during childhood. Several carcinogenic volatile nitrosamines have been 
detected in Chinese salted fish, although their precise role in inducing NPC remains 
to be determined (Henderson et al, 1976; Yu et al, 1988). 
 
Genetic susceptibility There is clear evidence for genetic susceptibility to NPC, and 
the existence of susceptibility genes at the HLA and cytochrome P4502E1 (CYP2E1) 
loci has been demonstrated by linkage analysis. These genes could account for the 
majority of cases of this cancer. The association between specific HLA antigens and 
NPC was first reported by Simons et al. in an investigation of 144 Chinese patients 
and 236 controls. Early evidence for a genetic determinant among Chinese was the 
identification of an HLA-associated increased risk of NPC associated with the joint 
occurrence of HLA-A2 and HLA-BSin2 (relative risk = 2.35) (Simons et al, 1976).    
Numerous studies conducted among Chinese NPC patients have indicated an 
association between HLA-A2/Bw46 and NPC (Chan et al, 1983; Simons et al, 1975), 
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but several studies conducted in non-Chinese NPC patients have reported associations 
with antigens other than HLA-A and HLA-B (Burt et al, 1994; Chan et al, 1985). In 
addition, the HLA types Aw19, Bw46, and B17 are associated with increased risk, 
while A11 is associated with a decreased risk of developing NPC. Ooi et al. reported 
that the NPC susceptibility gene may lie within the centromeric end of the class-I and 
the telomeric end of the class-III regions of the MHC, near the D6S1624 
microsatellite locus, where the presence of allele 4 of the microsatellite conferred a 
3.5-fold increase in the risk of NPC. This represents the highest reported risk for a 
single locus, while the presence of allele 1 of the same microsatellite conferred a 
highly significant protective effect against NPC (Ooi et al, 1997). A recent genome-
wide association study (GWAS) an additional three new susceptibility regions. This 
large GWAS, comprising approximately 5,000 patients and 5,000 controls of 
Southern Chinese descent, established beyond doubt that the HLA complex is a 
primary location for NPC risk, comprising multiple risk regions, with the top single 
nucleotide polymorphism (SNP) showing one of the highest statistically significant 
values of any published GWAS study (Bei et al, 2010). 
 
Other potential genetic markers in addition to HLA have been examined. Two studies 
have investigated the relationship between NPC and CYP2E1. A strong association was 
observed between the restriction fragment length polymorphisms detected by DraI and 
RsaI digestion of CYP2E1 in NPC (Hildesheim et al, 1995). A further case-control 
study conducted in 364 NPC patients and 320 control subjects reported that individuals 
homozygous for an allele of the CYP2E1 gene detected by RsaI digestion (C2 allele) 
had an increased risk of NPC (relative risk [RR] = 2.6; 95% confidence interval [CI] = 
1.2–5.7), suggesting that CYP2E1 genotype is a determinant of NPC risk (Hildesheim 
et al, 2002). A preliminary linkage study using 382 microsatellite polymorphism 
markers was performed in 23 Cantonese-speaking NPC pedigrees, and the 
susceptibility locus was mapped to chromosome 4p15.1-q12, strongly suggesting a 
putative NPC-susceptibility/related gene located at this region (Feng et al., 2002). 
Another linkage study by using multipoint linkage analysis, four loci (2q, 5p, 12p, and 
18p) showed LOD scores above 1.5. They reported one locus on 5p13 showed an 
increased LOD of 2.1 suggested a region on 5p13 may harbor a susceptibility gene 
for NPC(Hu et al, 2008). 
 
Comparative genomic hybridization (CGH) CGH has been used to investigate the 
genomic imbalance in many types of solid tumors (Kallioniemi, 2008; Kallioniemi et 
al, 1996; Kallioniemi et al, 1993), and numerous previously unrecognized recurrent 
genomic alterations have been detected using this approach, at sites potentially 
harboring oncogenes and putative TSGs. CGH has been applied by three different 
laboratories to detect chromosomal imbalances in NPC (Chen et al, 1999; Chien et al, 
2001; Fang et al, 2001; Hui et al, 2002). The most frequent chromosomal gains and 
allelic losses analyzed by CGH in NPC were summarized in Table 1. Comparison of 
these CGH results indicates that chromosome gains on chromosomes 1q, 3q, 11q, 12q 
and 17q are common genetic events in NPC. The high incidence of genetic 
amplification at multiple chromosomal regions strongly suggests that putative 
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oncogenes related to NPC tumorigenesis may map to these regions. CGH studies also 
identified allelic loss on several chromosome arms in NPC. These different CGH 
studies can be summarized in a similar result of allelic loss on 1p, 3p, 9p, 9q, 11q, 
13q, 14q, and 16q in NPC tumors, and were therefore in agreement with each other, 
and also in agreement with previous results of allelotyping analysis (Lo et al., 2000a; 
Shao et al., 2001; Shao et al., 2000) and LOH studies (Chan et al., 2002; Chan et al., 
2000; Lo & Huang, 2002; Lung et al., 2001; Mutirangura et al., 1996; Tsang et al., 
1999). These data strongly suggest that candidate TSGs in the deleted regions which 
might be involve in NPC pathogenesis and progression. 
 
Loss of heterozygosity (LOH) Cytogenetic studies of NPC xenografts identified 
changes on chromosomes 1, 3, 9, 11, 12, and 17. Consistent deletions on the short 
arms of chromosomes 3 and 9 suggest the presence of human suppressor genes 
residing in these regions and contributing to the malignant phenotype when the 
normal copy of the gene is deleted (Hui et al, 1999). Earlier LOH studies on primary 
NPCs from different laboratories observed high frequencies of allelic losses on 
chromosomes 3p (Deng et al, 1998; Lo et al, 1994; Lo et al, 2000a; Shao et al, 2000), 
9p (Chan et al, 2002), 11q (Lung et al, 2004), 13q (Mutirangura et al, 1999; Shao et al, 
2002; Tsang et al, 1999), and 14q (Cheng et al, 1997; Shao et al, 2002). These studies 
also revealed minimal deletion regions (MDRs) on high-frequency LOH autosomal 
arms that may contain tumor suppressor genes (TSGs) that contribute to NPC 
tumorigenesis. MDRs were 3p26 (homozygous deletion), 3p25.3-26.3, 3p25, 3p14.3-
24.1, and 3p14.2 on chromosome 3p (Chan et al, 2000; Deng et al, 1998; Lo et al, 1994; 
Lo et al, 2000a; Shao et al, 2000; Sung et al, 2000); 9p21-22 on chromosome 9p (Chan 
et al, 2002); 11q13.3-22 and 11q22-24 on chromosome 11q (Guo et al, 2001; Harn et 
al, 2002; Mutirangura et al, 1996); 13q12, 13q14, 13q14.3-22, and 13q31-34 on 
chromosome 13q (Tsang et al, 1999); 14q11, 14q12-13, and 14q32-ter on chromosome 
14q (Cheng et al, 1997). In addition, a high frequency of LOH on 3p has been reported 
in histologically-normal NPE(73.9%) and dysplastic NP lesions (75%) in Southern 
Chinese, whereas a significantly lower frequency of LOH on 3p was observed in 
normal NP from low-risk groups compared to high-risk groups (Chan et al, 2000). The 
presence of such genetic alterations in histologically-normal NP and dysplastic lesions 
suggests that it is an early event in tumor development.  
 
To further investigate the critical genetic events leading to tumor evolution, recent 
genome-wide allelotype analysis of primary NPCs revealed high frequency of LOH on 
chromosomes 1p, 3p, 3q, 9p, 9q, 11q, 13q, 14q, and 17q (Shao et al, 2000), with the 
highest frequencies of allelic deletions on 3p and 9p. In addition, LOH was also 
common on 4q, 5q, 8p, 11p, and 12p in NPC (Lo et al, 2000a; Shao et al, 2000).  The  
detailed mapping of these autosomal allelic losses and gains are summarized in Table 1. 
These high-resolution allelotyping and LOH analyses of NPC have generated an 
accurate and clear-cut profile of the chromosomal abnormalities in NPC, which should 
further investigations into the localization of putative tumor suppressor genes (TSGs) 
associated with the pathogenesis of NPC. The identification of multiple genetic losses 
in NPC tumors is consistent with a multi-step model of tumorigenesis, as in most other 
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solid tumors. Multiple chromosomal-region deletions in NPC may indicate multiple 
aberrations of TSGs or cancer-related genes located on these chromosomal arms, which 
may play important roles in the development and progression of NPC.  
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Table 1. Summary of genome-wide genetic alterations in NPC 
Original 
data 
Frequency of allelic 
losses  
MDRs  
Frequency of 
gains  
  MORs 
(CGH)  
Shao JY, 
et al. 
2000 
1p (65%), 2p (61%), 
2q (74%), 3p (91%), 
3q (71%), 5q (70%), 
9p (60%), 9q (69%), 
11q (77%), 13q 
(78%), 14q (79%) 
and 17q (60%). 
1p36, 2p25-p24, 
3p14-p21, 3p24-
p26, 5q11-q14, 
5q31-q33, 9p21-
p23, 9q33-q34, 
and 19q13. 
  
Lo KW, 
et al., 
2000a 
12q (70.4%), 13q 
(55.6%), 14q 
(85.2%) , 16q 
(55.6%),1p (37.0%), 
5q (44.4%), and 12p 
(44.4%) 
3p14-24.2, 
11q21-23, 13q12-
14, 13q31-32, 
14q24-32, and 
16q22-23 
  
Fang Y, 
et al., 
2001 
16q (55%), 14q 
(45%), 1p (43%), 3p 
(43%), 16p (40%), 
11q (36%), and 19p 
(34%)  
14q24-qter, 
1pter-p36.1, 
3p22-p21.3, 
11q21-qter, and 
the distal region 
of 19p 
 12q (51%), 4q 
(36%), 3q 
(34%), 1q 
(32%), and 18q 
(32%) 
  3q21--
q26.2, 
4p12--q21, 
8p, and 
12q14--q15 
Chien G, 
et al., 
2001  
3p14-p21 (20%), 
11q23-qter (20%), 
16q21-qter (17%) and 
14q24-qter (13%) 
3p12-14, 3p25-
26, 9p21-23, 
13q21-32, 
14q12-21, and 
11q14-23 
12p11.2-p12 
(36%), 12q14-
q21 (33%), 
2q24-q31 (23%), 
1q31-qter 
(20%), 3q13 
(20%), 1q13.3 
(20%), 5q21 
(17%), 6q14-q22 
(13%), 7q21 
(13%), 8q11.2-
q23 (13%) and 
18q12-qter 
(13%) 
12p12-13, 
1q21-22, 
17q21, 
17q25, 
11q13, and 
12q13 
Chen YJ, 
et al., 
1999 
3p (53%), 9p (41%), 
13q (41%), 14q 
(35%), and 11q (29% 
3p12-14, 3p25-
26, 9p21-23, 
13q21-32, 14q12-
21, and 11q14-23
12p (59%), 1q 
(47%), 17q (47%), 
11q (41%), and 
12q (35%).  
12p12-13, 
1q21-22, 
17q21, 
17q25, 
11q13, and 
12q13 
Abbreviations: LOH, loss of heterozygosity; CGH, comparative genomic 
hybridization; MDR, minimal deletion region; MOR, minimal overlapping region; 
NPC, nasopharyngeal carcinoma 
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Epigenetic changes in NPC 
Epigenetics refer to alternate phenotypic states that are not based on differences in 
genotype, and are potentially reversible, but are generally stably maintained during cell 
division. Among the epigenetic events, DNA hypermethylation has become one of the 
most dynamic and rapidly developing branches of molecular biology. Changes in DNA 
methylation are recognized as important events in normal and pathological cellular 
processes, contributing both to normal development and differentiation as well as 
cancer and other diseases. It has recently been suggested that cancer even be initiated as 
an epigenetic process before any mutations (Feinberg et al, 2006)  
 
In cancer, silencing of tumor suppressor genes or activation of oncogene is a main 
mechanism for carcinogenesis. It often coincides with the aberrant methylation of CpG 
dinucleotides in CpG islands, frequently located in promoters and transcription start 
sites of genes involved in various fundamental pathways, such as apoptosis, DNA 
damage repair, tumor invasion and metastasis. Aberrant methylation of tumor 
suppressor genes was frequently found in NPC. DNA methylation also plays an 
important role in the maintenance of specific EBV latency programs in the NPC cells.  
Thus, methylation profile of certain TSGs may serve as a complementary marker for 
identifying early cases. Many TSGs have been found to be frequently methylated in 
NPC, and the high detection rate in body fluids, such as saliva, brushings and plasma, 
suggested its potential application in non-invasive screening of NPC or detection of 
residual carcinoma after treatment (Chang et al, 2003). Combined analysis of five 
methylation markers (RASSF1A, p16, WIF1, CHFR and RIZ1) in brushings showed a 
good discrimination between NPC and non-NPC with a detection rate of 98% in a high 
risk population (Hutajulu et al). Moreover, hypermethylated promoter DNA of at least 
one of the three genes (CDH1, DAPK1, and p16) was detectable in post-treatment 
plasma of 5 of 13 (38%) recurrent NPC patients and none of the patients in remission, 
which suggested that cell-free circulating methylated gene promoter DNA is a potential 
useful serological marker in assisting in screening of potentially local or regional 
recurrent NPC (Wong et al, 2004). Multiplex methylation specific PCR (MMSP) for 
early diagnosis of NPC was developed to DNA derived from nasopharyngeal (NP) 
swabs. A panel of markers including two EBV genes (EBNA1 and un-methylated 
LMP1), and two-three cellular methylated TSGs (Rasff1A /DAPK and 
Rassf1A/DAPK/CHFR1) were simultaneously applied in this NPC-specific-MMSP 
assay through a single PCR reaction. The results showed that MMSP patterns of NPC 
swab were largely consistent with those of corresponding biopsies and significantly 
distinguished themselves from those of noncancerous volunteers. The sensitivity of 
detecting NPC from NP swabs is 98% (49 NPC and matched swabs, and 20 normal 
controls from Chinese), and 90% (37 NPC and 19 normal from Morocco)  (Zhang, 
2012, In press).  
 
In summary, NPC development may involve susceptibility gene mutations (major 
genes) and gene polymorphisms (minor-effect genes). In some familial cases, 
inherited genetic alterations (major gene transmission) could be the first “hit”, and 
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EBV infection may contribute to the second “hit”. Therefore, familial cases usually 
have a much younger age of onset. However, some other familial cases and probably 
most sporadic cases may get the first “hit” from both inherited genetic alterations 
(minor-effect genes, such as HLA, CYP2E1) and somatic genetic changes. In the high 
prevalence areas like south China, most of the NPC cases belong to this type and they 
usually have older age of onset than the familial cases with a major gene transmission 
(Figure 4) (Zeng & Jia, 2002). 
Figure 4. Putative model of genetic alterations, EBV infection and environmental 
factors involved in NPC development. Modified from “Pathology & Genetics, Head 
and Neck Tumor” (J.K.C. Chan, 2005; Zeng & Jia, 2002) 
 
Molecular Markers and Prognosis of NPC 
Genetic markers Certain genetic alterations in tumor cells can change the behavior of 
these cells, and these changes can be expected to be associated with certain clinical 
features. Cancer develops, at least in part, by an accumulation of genetic alterations that 
disrupt the normal processes of cell growth and differentiation. Previous molecular 
genetic and cytogenetic studies have demonstrated associations between LOH and 
tumor cell aggression, metastasis, clinical stage, and tumor differentiation in several 
types of cancers (Harada et al, 1999). A previous study found that progression of 
papillary renal cell carcinoma was associated with allelic loss on chromosome 9p21 
(Schraml et al, 2000). Rosin et al. performed an important LOH study on head and 
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neck squamous cell carcinoma (HNSCC), and reported that nearly 60% of 
premalignant lesions with LOH at 3p and/or 9p plus LOH at any other tested region 
developed HNSCC; among the lesions that later progressed to HNSCC, more than 70% 
exhibited this type of LOH profile (Rosin et al, 2000). This provides strong evidence 
for the effective use of LOH profiles to augment routine histopathological evaluation of 
oral premalignant lesions. Another LOH study of HNSCC reported that certain LOH at 
9p21, 3p and 17q13 tended to occur earlier in the progression pathway, whereas LOH 
at 13q11 and 8 usually occur late in the time course of progression. These results 
indicate that recurrent premalignant lesions arise from a common clonal progenitor, 
followed by outgrowth of clonal populations associated with progressive genetic 
alterations and phenotypic progression to malignancy (Califano et al, 1996; Chen & 
Chen, 2008). Nawrodz et al. reported that the presence of microsatellite alterations in 
serum DNA (shifts or LOH) was closely associated with advanced stages, metastasis, 
and poor prognosis in HNSCC patients, suggesting that the detection of microsatellite 
alterations in circulating tumor cell DNA may be useful for assessing tumor burden, 
metastatic status and overall prognosis (Nawroz et al, 1996). In a CGH study on 
HNSCC, Bockmühl et al. found that overrepresentations of 2q12, 3q21-29, 6p21.1, 
11q13, 14q23, 14q24, 14q31, 14q32, 15q24, 16q22, and deletions of 8p21-22 and 
18q11.2 were significantly associated with both shorter disease-free interval and 
disease-specific survival (DSS). Gains of 3q21-29, 11q13, and loss of 8p21-22 were 
independent prognostic markers carrying a higher significance than nodal status, as the 
only clinicopathological parameter with statistical importance. In addition, these three 
markers allowed a molecular classification of patients with low clinical risk (pN0 and 
pT2 tumors). Thus, genomic data derived from the evaluation of primary HNSCC has 
enabled patients to be stratified into subgroups with different survivals, highlighting the 
necessity of a genetically-based tumor classification system for refining the diagnosis 
and treatment of HNSCC patients (Bockmuhl et al, 2000). 
 
NPC is distinguished from other head and neck cancers by a number of 
epidemiological, histopathological and clinical characteristics. Few previous LOH 
studies have focused on the correlation between genetic alterations and clinical 
parameters in NPC. Recently, however, studies in our laboratory found that genetic 
alterations at certain chromosomal regions were associated with progressive clinical 
parameters in NPC. LOH analysis revealed that higher-frequency allelic losses at 
9p21 (56%) and/or 19q13 (50%) in NPC were correlated with primary tumor stage 
T3+T4 and advanced TNM stage (III+IV). High fractional allelic loss (FAL) value 
plus high antibody titers of EBV IgA/VCA and/or IgA/EA were significantly 
correlated with T3+T4 stage, distant lymph node metastasis, and advanced TNM 
stage in NPC. NPC patients with high titers of IgA/VCA and IgA/EA showed high 
frequencies of LOH on 16q (48%) and 19q13 (48%), and higher frequencies of LOH 
on 4q21 and 14q11-q12 were also found to be correlated with WHO type-III NPC 
histopathology (Shao et al, 2000). In a CGH study, Fang et al. reported that gain of 1q, 
8q, 18q, and loss of 9q were significantly associated with advanced clinical stage in 
NPC (Fang et al, 2001). In addition, Lo et al. detected high frequency of LOH at 3p 
in normal NPE (73.9%) and dysplastic lesions (75%) in Southern Chinese patients, 
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suggesting that LOH at 3p may be an early genetic event in NPC tumorigenesis 
(Chan et al, 2000).  
 
Plasma EBV-DNA marker  In addition to genetic and environmental factors, EBV 
infection has also been associated with the etiology of NPC (Liebowitz, 1994; Raab-
Traub et al, 1983). The detection of tumor-derived DNA in the plasma and serum of 
cancer patients suggests that polymerase chain reaction (PCR) amplification of EBV 
DNA may provide a feasible, minimally-invasive method for detecting and monitoring 
NPC. Using this method, Mutirangura et al. recently found EBV DNA in the serum of 
NPC patients, while Lo et al. detected circulating EBV DNA in 96% of NPC patients 
using real-time PCR technology (Lo et al, 1999b; Mutirangura, 2001).  
 
EBV-DNA level appears to be a prognostic factor, independent of any of the above-
mentioned factors, and it is thus likely that this parameter will be routinely assessed in 
the future, so increasing prognostic accuracy. The demonstration that tumor-derived 
DNA is detectable in the plasma and serum of cancer patients raises the possibility of 
non-invasive detection and monitoring of NPC. Using real-time quantitative PCR, cell-
free EBV DNA was found in the plasma of 96% of NPC patients and 7% of controls, 
while patients with advanced-stage NPC had higher plasma EBV-DNA levels than 
those with early-stage disease (Lo et al, 1999b). Further studies have demonstrated that 
EBV DNA may be a valuable tool for monitoring NPC patient response during 
radiotherapy (RT) and chemotherapy, as well as for the early detection of tumor 
recurrence (Lo et al, 1999a). In a cohort of 139 NPC patients treated with a uniform RT 
technique and followed up for a median of 5.55 years, serum circulating EBV DNA 
was found to be a significant prognostic indicator associated with NPC-related death 
according to Cox regression analysis, with a RR of 1.6 for each 10-fold increase in 
serum EBV-DNA concentration (Lo et al, 2000b). Quantitation of EBV DNA thus 
appears to allow improved prognostication of NPC. The sensitivity and specificity also 
suggest the potential use of EBV DNA as a screening test in areas where NPC is 
endemic. 
 
Histopathological Classification of NPC 
NPC has a dominant clinicopathological behavior characterized by easy invasion and 
metastasis, which differs from other head and neck cancers (Farias et al, 2003). 
Locoregional recurrence and distant metastasis are the two major reasons for failed 
treatment of NPC. Prognosis is currently based primarily on clinical TNM (Tumor, 
Node, Metastasis) staging (Heng et al, 1999; Hong et al, 2000; Sakata et al, 1999), but 
NPC is a heterogeneous cancer, and the clinical course can vary significantly among 
patients with the same clinical stage, suggesting that the TNM staging system is 
insufficient for precisely predicting disease outcomes. It is therefore necessary to 
identify molecular biomarkers that can help clinicians improve the prognostic 
prediction and develop therapeutic interventions for NPC patients. 
 
The current World Health Organization (WHO) histological classification system is 
insufficient for making a precise prognosis in NPC patients (Chan et al, 1998; Krueger 
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et al, 1981; Shanmugaratnam, 1978). The WHO classification defines NPCs as either 
keratinizing squamous cell carcinomas (KSCC) (2%) or non-keratinizing carcinomas 
(98%), with the latter subdivided into non-keratinizing differentiated carcinoma 
(NKDC) and non-keratinizing undifferentiated carcinoma (NKUC) (Shanmugaratnam 
et al, 1979). However, experienced pathologists have observed that NPC tumor cells 
exhibit obvious morphological variations; cells can be small and round, large and round, 
spindle-shaped, have vesicular nuclei, or be a mixtures of round and spindle-shaped 
cells. In light of observant these morphological heterogeneities, some pathologists have 
proposed a novel NPC histological classification system based on tumor cell 
morphology (Cammoun et al, 1978; Hsu et al, 1987; Shanmugaratnam et al, 1979; 
Sugano et al, 1978). However, these proposed histological classifications have not been 
accepted by NPC clinicians because the studies have involved limited numbers of cases, 
been single-center studies, or have lacked prognostic implications. Clinicians often 
appeal to pathologists to propose a new NPC histological classification system with 
improved prognostic accuracy that would permit more precisely personalized treatment. 
 
Molecular prognostic markers could potentially be represented by changes in gene-
copy number, mRNA, or protein expression levels. In the past decade, immunomarkers 
for tumor angiogenesis (lymphoangiogenesis) (Li et al, 2008; Ma et al, 2003), tumor 
cell proliferation, and apoptosis (survivin) (Ma et al, 2003; Taheri-Kadkhoda et al, 
2009), and tumor microenvironment factors including EBV infection, matrix 
metalloproteinase (MMPs) and their regulators CD147 and Cav-1 (Du et al, 2009; Yip 
et al, 2006), either alone or in combination, have been reportedly correlated with 
prognosis in NPC patients. However, despite extensive studies, these immunomarkers 
have produced inconsistent results, suggesting suboptimal prognostic values. Thus 
some clinicopathological features or immunomarkers have only weak, or controversial, 
prognostic value in NPC, and more specific clinicopathological features or 
immunomarkers are needed to enhance the prognostic value. This hypothesis has been 
tested at the mRNA level, whereas there is paucity of reliable IHC markers for 
predicting prognosis in other malignancies (Chen et al, 2007; Potti et al, 2006). 
 
Several supervised methods, such as decision trees, have been applied to the analysis of 
cDNA microarrays for refining prognosis in non-small cell lung cancer (NSCLC) 
(Boutros et al, 2009). A small subset of highly discriminating genes was recently 
shown to provide reliable cancer classifiers, by applying state-of-the-art support vector 
machines (SVM) classification algorithms, which are also effective for identifying 
informative features or attributes (such as critically important genes) (Spinosa & 
Carvalho, 2005). Using supervised SVM-based methods, we successfully developed 
three immunomarker-SVM-based prognostic characteristics that are closely associated 
with overall survival among patients with stage IB NSCLC (Zhu et al, 2009) . To date, 
supervised learning methods have not been used to develop highly predictive 
prognostic classifiers for NPC. To this end, we developed an immunomarker-SVM–
based NPC prognostic classifier (NPC-SVM classifier) for predicting survival of 
patients with NPC. 
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AIMS OF THIS THESIS 
 
The general objectives of this study were to characterize the morphological features of 
NPC; to identify common molecular markers involved in the pathogenesis and 
progression of NPC; and to propose an improved histological and molecular 
classifications of NPC. 
The specific aims were: 
1. To screen molecular biomarkers of loss of heterozygosity, gene expression and 
EBV related markers in NPC tumor. To evaluate these biomarkers (or biomarker 
panels) and their correlation to the clinical outcome and prognosis of the NPC 
patients. 
2. To develop an immunomarker-SVM-based prognostic classifier for NPC (NPC-
SVM-classifier) based on immunostained differentially expressed genes in NPC 
and the support vector machines (SVM)-based methods 
3. To investigate the expression of LMP1 in NPC cells and its functional role in 
development and progression of NPC. 
4. To propose a new histological classification system for NPC based on 
morphological characteristics, tumor cell differentiation, and epithelial-
mesenchymal transition (EMT) morphology. 
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RESULTS AND DISCUSSION 
 
Caveolin-1 and CD147 Expression in NPC (Paper I) 
Cav-1 is a major structural component of caveolae, which are involved in several 
cellular functions, including vesicle trafficking, cholesterol homeostasis and signal 
transduction (Anderson, 1993; Okamoto et al, 1998). Reduced Cav-1 expression has 
been reported in ovarian cancer (Wiechen et al, 2001), and lung cancer (Sunaga et al, 
2004). In contrast, Cav-1 overexpression has been observed in bladder cancer 
(Sanchez-Carbayo et al, 2002), prostate cancer (Li et al, 2001) and esophageal 
squamous cell carcinoma (ESCC) (Kato et al, 2002). Furthermore, recent evidence 
suggests a central role for Cav-1 in the regulation of cellular invasion and metastasis 
(Li et al, 2001; Lu et al, 2003; Williams et al, 2004; Zhang et al, 2000). Cav-1 
overexpression in tumor cells has also been correlated with poor prognosis in patients 
with ESCC (Kato et al, 2002), renal clear cell carcinoma (Joo et al, 2004), prostate 
cancer (Yang et al, 1999), lung cancer (Yoo et al, 2003), and pancreatic ductal 
adenocarcinoma (Suzuoki et al, 2002). In the current study, Cav-1 overexpression in 
NPC tumor cells was significantly correlated with recurrence (p = 0.038) and 
metastasis (P = 0.025) of the disease, and with poor prognosis.  
 
Extracellular matrix metalloproteinase inducer (EMMPRIN), also named CD147, is a 
glycoprotein that belongs to the immunoglobulin superfamily (Biswas et al, 1995). 
CD147 is composed of two extracellular Ig domains, a single transmembrane domain, 
and a short cytoplasmic domain. The first Ig domain is required for counter receptor-
binding activity, which is involved in MMP induction and oligomerization, while the 
second Ig domain is known to associate with Cav-1 (Tang et al, 2004a). CD147 is 
enriched in the plasma membrane of tumor cells and triggers the production or release 
of MMPs in surrounding mesenchymal and tumor cells (Guo et al, 2000; Kanekura et 
al, 2002). Several recent studies have found that overexpression of CD147 is correlated 
with poor prognosis in human cancers, including ESCC (Ishibashi et al, 2004), breast 
carcinoma (Reimers et al, 2004), serous ovarian carcinoma (Davidson et al, 2003) and 
gastric carcinoma (Zheng et al, 2006). Overexpression of CD147 in tumor cells has 
been reported to be correlated with metastasis of breast cancer (Reimers et al, 2004) 
and oral squamous cell carcinoma (Bordador et al, 2000), and with poor prognosis in 
patients with ESCC (Ishibashi et al, 2004), breast cancer (Reimers et al, 2004), serous 
ovarian cancer (Davidson et al, 2003) and gastric cancer (Zheng et al, 2006). CD147 
overexpression in NPC tumor cells was significantly correlated with metastasis (P = 
0.017) and poor prognosis in NPC patients in the present study.  
 
NPC patients overexpressing both Cav-1 and CD147 in tumor cells had significantly 
poorer prognoses and significantly lower 5-year overall survival rates relative to NPC 
patients with lower expression levels of both Cav-1 and CD147 (45.17% vs. 68.32%, P 
= 0.004). To the best of our knowledge, this represents the first report of Cav-1 and 
CD147 overexpression and their significance with respect to metastasis and prognosis 
in NPC. These results are consistent with previous studies of Cav-1 and CD147 
expression in other malignancies. This is interesting in view of that these two genes 
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may play key roles in the invasion and metastasis of NPC, and correlate with poor 
prognosis in NPC patients.  
 
The results of the current study showed that siRNA-mediated inhibition of Cav-1 
expression in human NPC cell lines led to significant downregulation of CD147 protein 
expression (45%, CNE1; 58%, CNE2), while Cav-1 overexpression led to significant 
upregulation of CD147 protein expression (2.8-fold, CNE1; 1.7-fold, CNE2). Cav-1 
expression positively correlated with CD147 expression in NPC tumor cells (ρ = 0.330, 
P = <0.001). These results indicate that Cav-1 regulates the expression of CD147 in 
NPC cell lines, and one of the roles of Cav-1 in NPC carcinogenesis may thus be partly 
mediated by upregulation of CD147 expression. Growing evidence suggests a novel 
association between Cav-1, CD147 and the expression or secretion of MMPs. 
Overexpression of Cav-1 in HEK293 cells decreased MMP-1 secretion in a co-culture 
assay with primary human fibroblasts (Tang & Hemler, 2004), and overexpression of 
Cav-1 in metastatic mammary tumor cells could inhibit MMP-2 and MMP-9 secretion, 
although the expression of MMP-2 and MMP-9 in whole cell lysates was not altered. In 
contrast, Cav-1 induced MMP-11 secretion and invasive potential in a murine 
hepatocarcinoma cell line (Jia et al, 2006). CD147 is a tumor-cell-derived MMP 
inducer that is expressed on the tumor cell surface and triggers the production or release 
of MMP-1, MMP-2, MMP-3, MMP-9, MT1-MMP and MT2-MMP in the surrounding 
mesenchymal and tumor cells (Guo et al, 2000; Kanekura et al, 2002; Sameshima et al, 
2000; Tang et al, 2004b; Yang et al, 2003). The current study found that suppression of 
Cav-1 and CD147 expression led to decreased MMP3 and MMP11 secretion in CNE1 
and CNE2 cells, whereas overexpression of Cav-1 in CNE1 and CNE2 cells promoted 
MMP3 and MMP11 secretion. Transwell migration assays further revealed that loss of 
Cav-1 and CD147 expression inhibited CNE1 and CNE2 cell-migration ability, 
whereas Cav-1 overexpression promoted cell-migration ability. These results indicate 
that Cav-1 and CD147 overexpression in NPC tumors can promote tumor-cell 
migration by stimulating MMP3 and MMP11 secretion by NPC tumor cells.  
 
In summary, this study demonstrated that overexpression of Cav-1 and CD147 (MMP 
regulators in tumorigenesis) were closely correlated with local relapse, metastases, and 
poor prognosis in NPC patients. These biomarkers render tumor cells somewhat 
resistant to the conventional therapies including radiotherapy and/or chemotherapy.  
One way out of this would be to consider therapy with targeted antagonists of these 
molecules. 
 
Correlation between LOH, Clinicopathological Parameters and EBV Infection in 
NPC (Paper II) 
 NPC is distinguished from other head and neck cancers by a number of 
epidemiological, histopathological and clinical characteristics. Certain genetic 
alterations in tumor cells can change their behavior, and these changes might thus be 
expected to be associated with certain clinical features. Cancer develops, at least in 
part, as a result of an accumulation of genetic alterations that disrupt the normal 
processes of cell growth and differentiation. It has been proposed that chromosomal 
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loss is often correlated with tumor histopathology, staging and other tumor clinical 
characteristics in a number of human cancers. A previous study showed that 
progression of papillary renal cell carcinoma was associated with allelic loss on 
chromosome 9p21 (Schraml et al, 2000), and LOH at chromosome 18q has been 
reported to be associated with poor prognosis in cancer of the cervix (Kersemaekers 
et al, 1998).  
 
To demonstrate a comprehensive profile of LOH in NPC, we applied a large panel of 
400 microsatellite polymorphism markers in 98 cases of sporadic primary NPC. Of 
the 335 informative markers, 83 loci showed high levels of LOH (present in more 
than 30% of cases) and most of the high-frequency loci were clustered to 
chromosomes 1p36 and 1p34, 3p14-p21, 3p24-p26, 3q25-q26 and 3q27, 4q31 and 
4q35, 5q15-21and 5q32-q33, 8p22-p23, 9p21-p23 and 9q33-q34, 11p12-p14, 13q14-
q13 and 13q 31-q32, 14q13-q11, 14q24-q23 and 14q32. Higher frequencies of LOH 
were found on chromosomes 3, 5, 9 and 11 (≥50%), while medium frequencies of 
LOH were found on chromosomes 1, 4, 6, 14, 17 and 19 (49–49%). Several new 
regions showing high frequencies of LOH were found on chromosomes 1p36, 3q25-
q26, 3q27, 5q15-q21, 8p22-p23, 9q and 11p12-14 (Shao et al, 2000). The detailed 
allelic deletion map for NPC is shown in Figure 5. 
Figure 5. Detailed allelic deletion map of chromosomal arms in NPC (Shao et al, 
2001).  
 
Our study found a significantly higher incidence of LOH on chromosomes 9p21 and 
19q13 in T3+T4-stage NPC compared to T1+T2-stage NPC, suggesting that allelic loss 
in these regions may correlate with the invasive progression of NPC (Figure 6A). We 
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also found a significantly higher mean fractional allelic loss (FAL) value (0.56 ± 0.11) 
in NPC stage T3+T4, compared to NPC stage T1+T2 (0.48 ± 0.1). In addition, one 
locus on 19q13 (D19S210) had a significantly higher LOH frequency in advanced stage 
(III+IV) NPC (46%, 12/26), whereas no LOH was observed in 13 cases of early-stage 
NPC (I+II) at this locus (p=0.002) (Figure 6C). These results suggest that the 
accumulation of LOH at specific chromosomal regions in NPC may result in a more 
aggressive population of tumor cells, which may be correlated with specific TSG 
inactivation and progression of NPC.  
 
In this study, significantly higher frequencies of LOH were observed on 16q and 19q13 
in NPC patients with high antibody titers of EBV IgA/VCA (≥1:640) and/or IgA/EA 
(≥1:80) compared to patients with low antibody titers of EBV IgA/VCA (≤1:320) 
and/or EA/IgA (≤1:40) (Figure 6D). In addition, tumors in the NPC group with both 
higher FAL values (≥0.52) and higher antibody titers of EBV IgA/VCA (≥1:640) 
and/or IgA/EA (≥1:80) showed more aggressive behavior at T, N, and TNM stages, 
compared to NPC tumors with lower FAL values (<0.52) and/or lower antibody titers 
of EBV IgA/VCA (≤1:320) and/or EA/IgA (≤1:40). Because both EBV infection and 
genetic alterations play important roles in the etiology of NPC, these data suggest a 
possible counteracting role of genetic factors in NPC tumorigenesis. It is possible that 
LOH may be a more important factor than EBV infection in the development of NPC 
in those patients with lower serological antibody titers of EBV IgA/VCA and IgA/EA, 
and with higher frequencies of LOH at specific chromosomal regions. In contrast, EBV 
infection may be more important than LOH in NPC tumorigenesis in patients with 
higher serological antibody titers of EBV IgA/VCA and IgA/EA and lower frequencies 
of LOH at specific chromosomal regions. The correlation between LOH (at loci with 
LOH frequency ≥30%) and NPC clinicopathological parameters is shown in Figure 6.  
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Figure 6, Correlations between LOH and clinicopathological parameters in NPC (Shao 
et al, 2001). 
 
 FAL was calculated for each tumor according to the number of autosomal arms 
displaying LOH, divided by the number of informative autosomal arms. FAL reflects 
the quantity of genetic abnormalities in each tumor (Choi et al, 1998; Field et al, 1996). 
The FAL values varied among the 61 NPCs, ranging from 0.23 (9/39) to 0.77 (30/39), 
with a median value of 0.51 and a mean value of 0.52 ± 0.12. This indicates that, on 
average, each tumor showed LOH on 52% of its autosomal arms. FAL values were 
significantly correlated with T stage in NPC, i.e., the mean FAL value was 0.56 ± 0.11 
in stage T3+T4 NPC, compared to 0.48 ± 0.1 in stage T1+T2 NPC (p=0.01).  
 
In conclusion, high frequencies of LOH (≥60%) were observed in NPC. LOH at 
specific chromosomal regions has been shown to correlate with a number of clinical 
features in NPC, i.e., aggressive and progressive behavior, histopathology, and tumor 
differentiation. Determination of the specific genetic markers by LOH, CGH, and 
linkage analysis will not only improve our understanding of the genetic epidemiology 
of NPC, and also provide additional indicators for earlier diagnosis and prognosis of 
this cancer. Moreover, accumulation of these genetic markers may be useful for the 
development of an NPC molecular staging system, which could improve the current 
clinicopathological classification and staging systems.  
 
EBV Infection and its Relations to Apoptosis and Lymphocyte Infiltration in NPC 
(Paper III)  
LMP1 is known to modulate several key pathways controlling transcriptional 
activity and cell life/death relevant to tumor cell biology, such as the nuclear factor 
(NF)-kB (Brinkmann et al, 2003), AP-1 (Kilger et al, 1998), JNK (Eliopoulos et al, 
1999), Jak/STAT (Gires et al, 1999) and TRADD/TRAF pathways (Kieser, 2008; 
Schneider et al, 2008). LMP1 can thus protect B cells and epithelial cells from 
apoptosis (Fries et al, 1996). Furthermore, sequence variations found in the LMP1 
gene in NPC tumors may reflect mutations affecting LMP1 function and/or 
immune surveillance, with significance for NPC tumorigenesis (Hu et al, 2000). In 
this study, we explored the expression of markers related to cell proliferation, 
apoptosis, immune response, stromal interactions, and EBV-gene expression in a 
large group of NPC biopsies, in relation to LMP1 expression, using a qualitative 
and semi-quantitative IHC approach. 
 
The results demonstrated high levels of p53 expression in most NPC biopsies, 
together with Ki67, which correlated with LMP1 expression and a reduction in 
apoptosis. Thus increased p53 did not appear to lead to either cell cycle arrest or an 
increase in apoptosis. This suggests overexpression of a seemingly inactive p53, as 
has often been observed in other tumors (Levine, 1990; Lutzker & Levine, 
1996)Levine et al., 1997). However, the mechanisms leading to p53 overexpression 
are unclear. Crook et al. (2000) found that p53-related p63 was invariably 
expressed in NPC biopsies in a truncated form, called the deltaN-isotype, which is 
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able to block p53-mediated transactivation. p63 was therefore suggested to be a 
suppressor of wild-type p53 function in NPC tumors, but this is not known to be 
LMP1-related (Crook et al, 2000). However, LMP1 may block p53-triggered 
apoptosis by induction of A20, as seen in epithelial cells in vitro (Codd et al, 1999; 
Fries et al, 1996). 
 
In addition to measuring the apoptotic index by terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) assay, the steady state expression 
levels of five key regulators of apoptosis, Fas-ligand (FasL), Fas, Bcl-2, Bax, and 
caspase 3, were also analyzed in situ in NPC biopsies. FasL, Bax and caspase 3 
expression may all relate to increased apoptosis, while Bcl-2 blocks apoptosis. Bcl-
2 and Bax are opposing modulators of the former, while the Fas-FasL system 
represents the latter type of system. Both types of pathways converge to activate 
cleavage of caspase 3, which is the main downstream effector of many of the 
molecular and phenotypic effects seen in apoptosis. Our results indicated that 
apoptosis was significantly reduced in LMP1-expressing NPCs compared to 
LMP1-negative ones. As already stated, this in turn correlated with increased p53 
expression, probably due to overexpression of a functionally-modified or inactive 
p53. This suggests that caspase 3 expression might be increased in LMP1-negative 
tumors, as found. However, a steady state level of caspase 3 does not necessarily 
have to correlate with a higher apoptotic activity, because activation requires 
cleavage; caspase 3 was also increased in LMP1-negative tumors with high level of 
FasL.  
 
The observed negative correlation between FasL and LMP1 is interesting. LMP1 is 
known to modulate and interact with one of the apoptosis pathway channeled 
through the tumor necrosis factor (TNF)-receptor complex, because LMP1 
physically binds via COOH-terminal activation regions (CTARs) to TNFR-
associated death domain protein (TRADD) and tumor necrosis factor receptor 
(TNFR)-associated factors (TRAFs) (Kieser et al, 1999). Fas-FasL operates 
through a parallel pathway, which overlaps with the TNF-receptor pathway 
downstream. In an in vitro transfected epithelial cell system, we observed that 
LMP1 may show an additive effect to Fas-mediated apoptosis (unpublished data), 
suggesting that LMP1-positive tumors show selection against FasL-expressing cells.  
 
The number of CD8+ T lymphocytes infiltrating within tumor cell nests was 
significantly higher in LMP1-positive compared to LMP1-negative tumors. CD25+ 
and TIA-1+ cells were not increased in the cancer nests, compared to normal tissue, 
indicating that the infiltrating T cells were mostly not activated, which is in 
agreement with the lower levels of apoptosis in these LMP1-positive tumors. 
However, activated CD8+ cells were consistently seen in close proximity to 
apoptotic bodies or cells with nuclear DNA fragmentation (TUNEL+), suggesting 
cell-mediated killing of some neoplastic target cells. This differs from the situation 
in Hodgkin’s disease (HD), where predominantly CD4+ T cells were found (Frisan 
et al, 1995). LMP1-positive cells can be targets of specific killer T cells but, as 
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observed in HD (Dolcetti et al, 1995), the T cells may be predominantly anergic. In 
contrast to NPC, CD8+ T cells in EBV-associated gastric cancer showed a 
relatively high level of proliferative activity, suggesting an activated state 
(Kuzushima et al, 1999). 
 
Blocking of apoptosis has been shown to be an important factor in tumor progression. 
LMP1-positive tumors showed reduced apoptosis correlated with lower caspase 3 
levels, overexpression of p53, and reduced FasL expression. This may explain the 
prognostic difference in clinical phenotypes between LMP1-positive and LMP-negative 
tumors. The role of the large fraction of infiltrating T cells is unclear, but our findings 
suggest that they are predominantly inactive and may thus not kill the tumor cells. 
However, as already suggested, they may contribute locally via cytokines that could 
promote tumor growth. In addition, the correlation of LMP1 positivity with higher 
MMP-9 expression supports our earlier observation, that LMP1-positive tumors grow 
larger and show a higher degree of invasiveness (Hu et al, 1995).  
 
As mentioned, a difference in the growth pattern and clinical course of EBV-LMP1 
expressing and non expressing NPCs has been observed (Hu et al., 1995). In this study, 
we are not able to link the MMP-9 expression results with invasion and metastasis 
because of the lack of clinical data.  Our results may provide one of mechanism of 
LMP1 function via induction of invasion by elevated expression of MMP9.  
 
Plasma EBV DNA as a Prognostic Predictor in NPC (Paper IV) 
The presence of tumor-derived DNA in the plasma and serum of cancer patients raises 
the possibility for an approach to minimize invasive methods  in monitoring of this 
disease (Nawroz et al, 1996). Because NPC has a close association with EBV, 
measurement of plasma EBV DNA represents a potentially feasible method of 
identifying these tumors. We demonstrated that EBV DNA could be detected in the 
plasma of 96% of patients with primary NPC, and 100% of those with locally-recurrent 
and distant metastatic tumors. In contrast, EBV DNA was detected in much lower 
percentages in control subjects and patients with clinically-remissive NPC. These 
results are consistent with those of Lo et al. (Lo et al, 2000b; Lo et al, 1999b), who 
detected plasma EBV DNA in 96% of NPC patients. This suggests that EBV DNA 
could be used as a serological marker for NPC diagnosis and prognosis. In the current 
study, two of the control subjects had high levels of plasma EBV-DNA, and it is worth 
noting that both these subjects were later diagnosed with NPC by histological 
examination of biopsy specimens. This further suggests that quantitative analysis of 
plasma EBV DNA may provide a sensitive method for screening patients for NPC. 
This would be especially valuable in areas where this disease is endemic, such as in the 
Guangdong province of southern China.  
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Figure 7. Variations in plasma EBV-DNA levels and EBV IgA/VCA antibody titers 
among different NPC subjects. Plasma EBV-DNA levels declined to 0 copies/ml in 
clinically-remissive NPC (subject 4) and in patients after completion of RT (subject 3), 
but increased to high levels after local recurrent (subject 5) and distant metastatic NPC 
(subject 6). However the EBV IgA/VCA antibody titer remained at high levels in all 
NPC groups (7A). The plasma EBV-DNA could only be detected in 23% of NPC after 
completion of radiotherapy and 12% of clinically remissive NPC, while  all the NPC 
subjects maintained high IgA/VCA antibody prevalence (7B) (Shao et al, 2004b).  
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Figure 8. Plasma EBV-DNA levels and VCA/IgA titers (geometric mean) in NPC 
patients with different TNM stages. Plasma EBV-DNA levels increased significantly 
with tumor progression according to TNM stage (8A), T stage (8B), and N stage (8C). 
NPC patients with different organ metastases presented different plasma EBV-DNA 
concentrations (8D). Though VCA/IgA increased significantly in advanced TNM stage 
NPC, it shows no difference in different T and N stage NPC as well as in patients with 
distant metastasis (8A–8D) (Shao et al, 2004b).  
 
Serological surveys and follow-up studies of NPC in China have been widely used to 
verify VCA/IgA and IgA/EA titers as valuable markers for the screening and early 
diagnosis of NPC (Deng et al, 1995; Zeng et al, 1983). The current results 
demonstrated a positive correlation between plasma EBV-DNA concentration and 
serum EBV VCA/IgA antibody titers in patients with primary NPCs. However, while 
RT and clinical remission of NPC reduced plasma EBV-DNA concentrations, in some 
cases to undetectable levels, EBV VCA/IgA levels remained high in these patients. 
These results indicate that plasma EBV DNA is a more sensitive and valuable marker 
than serum VCA/IgA for monitoring therapeutic effects and prognosis in NPC.   
 
The China 92 TNM staging system has been used to determine the prognosis of NPC in 
China. The 5-year survival figures for stages I, II, III, and IV NPC have been reported 
to be 95%, 78%, 49%, and 23%, respectively (Hong et al, 2000; Min et al, 1994). We 
found a positive correlation between plasma EBV-DNA titer and TNM stage, as well as 
between plasma EBV-DNA concentration and T or N stage. In contrast, although 
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VCA/IgA geometric mean titer (GMT) was higher in advanced TNM stage compared 
to early-stage NPC, there was no significant correlation between VCA/IgA GMT and T 
or N stage NPC. The finding that plasma EBV-DNA concentration could be correlated 
with tumor progression, especially in primary tumor T stage, strongly suggests that 
plasma EBV DNA may be an independent prognostic indicator for staging of NPC. In 
addition, the strong correlation between plasma EBV-DNA concentrations and TNM 
stages, especially T stage, suggests that the level of circulating EBV DNA may reflect 
tumor burden. Thus, plasma quantitative analysis of EBV DNA may be more useful 
than VCA/IgA for enhancing the traditional TNM staging system at the molecular level. 
 
NPC is a radiosensitive cancer and RT is usually the most effective treatment modality 
for this cancer. To date, however, there has been no accurate way of evaluating the 
radiotherapeutic effects on NPC. We observed that plasma EBV DNA disappeared in 
77% of NPC patients after RT, and the mean concentration decreased sharply from 
13,330 copies/ml prior to treatment to 0 copies/ml after completion of RT. This sharp 
reduction or disappearance of plasma EBV DNA in NPC patients after RT suggests 
that kinetic analysis of circulating EBV DNA during treatment may provide a powerful 
tool for evaluating the in vivo response of NPC to anti-neoplastic treatments. 
 
Local tumor recurrence, regional lymph node involvement, and distant metastasis of 
NPC are events that result primarily from failing treatment response. It has been 
estimated that about 80% of NPC patients succumb to tumor with recurrence and/or 
distant metastases die (Chua et al, 2001). Thus, earlier detection of tumor recurrence or 
distant metastases is crucial for improving the overall survival rates of NPC patients. 
The detection of plasma EBV DNA in all eight NPC patients with recurrent tumors, but 
in only 12% of those with clinically-remissive disease, suggests that monitoring of 
plasma EBV DNA may provide a useful method for the early detection of tumor 
recurrence or metastasis. Of the seven clinically-remissive NPC patients with high 
plasma EBV-DNA concentrations, three were later confirmed histologically to have 
local tumor recurrence, while one patient had clinically-confirmed liver metastasis 
within 3 months of follow-up. Lo et al. (Lo et al, 1999b) also reported a gradual 
increase in serum EBV-DNA concentrations in individuals who later developed tumor 
recurrence. Our results thus confirm the fact that elevated plasma EBV-DNA levels 
precede the histological signs of tumor recurrence or progression in patients with NPC. 
Our investigation also enlisted 21 NPC patients with clinically-confirmed liver, brain, 
lung and bone metastases. The plasma EBV-DNA levels in NPC patients with liver 
metastases were about 3-fold higher than in those with lung metastases, and 16-fold 
higher than in those with bone metastases alone. These results indicate that regular 
assessment of plasma EBV-DNA levels in NPC patients after RT may enable earlier 
detection of local recurrence and distant metastasis.  
 
EBV LMP1 Regulates Mammalian Target of Rapamycin (mTOR) Signaling-
Pathway Molecules in NPC (Paper V) 
The mammalian target of rapamacin (mTOR) is an evolutionarily-conserved 
serine/threonine protein kinase with an important role in cell growth and proliferation, 
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which acts through regulation of ribosome biogenesis and protein translation (Tsang et 
al, 2007). PI3K/AKT is considered a critical upstream mediator of the mTOR signaling 
pathway. The characterized downstream effectors of mTOR are ribosomal P70S6K, 
and eukaryotic initiation factor 4E (eIF4E)-binding protein (4E-BP1), with eIF4E 
dissociating from 4E-BP1 to initiate translation after 4E-BP1 phosphorylation, while 
P70S6K translates mRNA transcripts with a 5’-TOP motif following 
hyperphosphorylation by mTOR (Goberdhan & Boyd, 2009; Hay & Sonenberg, 2004). 
 
As a well-known oncogene, one of the functions of LMP1 is to promote cell 
proliferation in NPC (Dirmeier et al, 2005; Faqing et al, 2005). The mTOR signaling 
pathway is also a major effector in cell growth, cell proliferation and cell survival, 
through regulation of protein synthesis, while P70S6K and 4EBP1 play particularly 
important roles in the growth-acceleration function of the mTOR signaling pathway 
(Tsang et al, 2007). Our findings suggest that activation of P70S6K and 4EBP1 
requires LMP1, and that when these genes are phosphorylated via LMP1, activated 
P70S6K and 4EBP1 initiate a sequence of events that promotes protein synthesis, cell 
growth and proliferation. Further studies are needed to investigate the mechanism 
whereby LMP1 regulates mTOR signaling in NPC tumorigenesis. 
 
Previous studies have reported the involvement of LMP1 in several signaling pathways, 
including NF-κB, AP-1, JAK/STAT, PI3K/AKT and ERK-MAPK (Dawson et al, 2008; 
Dawson et al, 2003; Mainou et al, 2005; Zheng et al, 2007). LMP1 activates the 
PI3K/AKT/mTOR signaling pathway in B lymphocytes (Lambert & Martinez, 2007), 
and the mTOR signaling pathway has been identified as a downstream component of 
the PI3K/AKT pathway in the LMP2A-transfected NPC cell lines HONE1 and AD/AH 
(Moody et al, 2005). The mTOR signaling pathway might also positively regulate 
cyclin D1 expression in NPC (Huang et al, 2009). In our study, microarray analysis of 
the NPC HONE1 cell line stably-transfected with LMP1 identified several 
differentially-expressed genes associated with mTOR signaling pathways. This is the 
first report to demonstrate that LMP1 can regulate the mTOR signaling pathway in 
NPC. Furthermore, LMP1 overexpression and knockdown studies confirmed that 
LMP1-regulated genes were involved in the mTOR signaling pathway, and that LMP1 
expression was essential for the activation of p-mTOR and p-4EBP1 in NPC cell lines. 
In addition, our in vitro studies found that LMP1 expression was positively correlated 
with overexpression of p-mTOR, p-P70S6K and p-4EBP1 in NPC tumors. 
 
Deregulation of the mTOR signaling pathway has been reported in many malignancies, 
and some of the signaling molecules in this pathway are predictors of prognosis in 
different types of cancers. Cytoplasmic p-mTOR expression correlates with poorer 
survival in gastric cancer and cervix adenocarcinoma (Faried et al, 2008; Murayama et 
al, 2009), while high expression of p-mTOR, p-P70S6K and p-4EBP1 correlate with 
poor outcome in glioblastoma (Pelloski et al, 2006). Our results revealed that NPC 
patients with high p-P70S6K and p-4EBP1 expression levels had a significantly shorter 
overall survival than those with low p-P70S6K (p = 0.049) and p-4EBP1 (p = 0.010) 
expression levels. These results are in accordance with previous studies on 
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malignancies. High expression levels of p-P70S6K and p-4EBP1 in NPC tissues might 
result in high levels of protein synthesis and cell proliferation, as well as poor prognosis 
in NPC patients. 
 
Figure 9. Kaplan-Meier curves of overall NPC patient survival. A, Five-year overall 
survival rates were 54% in patients with NPC tumors expressing high levels of LMP1 
(n = 141), and 68% in patients with low LMP1 (n = 83) (p = 0.020). B, Five-year 
overall survival rates were 55% in patients with NPC tumors expressing high levels 
of p-mTOR (n = 109), and 62% in patients with low p-mTOR (n = 114) (p = 0.311). 
C, Five-year overall survival rates were 49% for patients with NPC tumors expressing 
high levels of p-P70S6K (n = 106), and 69% for patients with low p-P70S6K 
expression (n = 118) (p = 0.049). D, Five-year overall survival rates were 49% in 
patients with NPC tumors expressing high levels of p-4EBP1 (n = 128), and 71% in 
patients with low levels of p-4EBP1 (n = 95) (p = 0.010).
 
In this study, IHC staining of LMP1 was performed in a large sample of NPC cases, 
and LMP1 overexpression was detected in 62.9% (141/224) of NPC tumors, in 
accordance with previous studies (Horikawa et al, 2001; Jeon et al, 2004; Shao et al, 
2004a). Interestingly, LMP1 overexpression was significantly associated with poorer 
overall survival in NPC patients (p = 0.020). This result differed from previous reports, 
which found that LMP1 overexpression was associated with a better prognosis in NPC 
patients (Hu et al, 1995), or that LMP1 was not an effective indicator of NPC outcomes 
(Sarac et al, 2001). These differences might be attributable to different sample sizes, 
regional distributions, or different LMP1 variants. Although high expression levels of 
LMP1, p-P70S6K and p-4EBP1 were associated with poor survival in NPC patients, 
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multivariate analysis only identified LMP1 expression, as well as gender (p = 0.014) 
and metastasis (p = 0.003), as independent prognostic factors. The mTOR signaling 
pathway was triggered by LMP1, supporting that LMP1 may have a more important 
role than mTOR signaling molecules in the carcinogenesis and development of NPC. 
 
Molecular Classification of NPC (Paper VI) 
SVM has recently shown promise for the analysis of microarray data. Compared to 
other machine-learning algorithms such as decision trees, artificial neural networks, and 
nearest-neighbor classifiers, SVM is well suited to managing classification problems, 
including high-dimensional data and limited number of training samples. Another 
important use of SVM is to select several efficient features from all available features 
(Vapnik & Chapelle, 2000; Vapnik, 1999). A single gene expression does not have 
enough predictability power. Genes are not independent from each other; only with 
several genes can we obtain satisfactory and reliable prediction of prognosis. With 
SVM, clinicopathological features can be combined with predominant genes to predict 
the outcome of patients. Moreover, it also excludes the problem of cut-off point of 
immunomarkers. 
 
The ability to treat patients according to their molecular characteristics is becoming a 
trend in cancer research (Boutros et al, 2009; Potti et al, 2006; Sotiriou & Piccart, 
2007). NPC is a clinically heterogeneous disease and outcomes vary even among 
patients with similar clinical stages; some are cured, whereas the cancer recurs in others. 
In our study, we developed an immunomarker-SVM-based NPC prognostic classifier 
(NPC-SVM classifier) for predicting survival in NPC patients. The reported NPC-SVM 
classifier integrates seven genes: SPARC, survivin, MMP11, caveolin-1, CD147, 
LMP1, and p-P70S6K, together with gender. The NPC-SVM classifier was closely 
correlated with clinicopathological outcomes in NPC patients. These results suggested 
that the NPC-SVM-classifier of NPC could select powerful factors predictors of 
prognosis of NPC patients. 
 
The developed eight-signature NPC-SVM classifier can categorize NPC patients into 
high-risk and low-risk groups with significantly different prognoses in terms of 5-year 
DSS. This classifier also has high sensitivity (79.5%) and specificity (82.4%) for 
predicting survival of NPC patients. These results indicate that the NPC-SVM classifier 
can better reflect the nature of disease progression in NPC patients. Moreover the NPC-
SVM classifier retained significant prognostic value after stratification by gender, 
clinical stage, age, and therapeutic method, except in NPC patients with early-stage 
tumors, and in patients with radiochemotherapy (RCT) treatment. These results provide 
clinicians with a credible, applicable molecular classification for better prognostic 
prediction in NPC patients. This represents the first large-sample study on the 
molecular classification of NPC. 
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Figure 10. Receiver operating characteristic (ROC) curves and Kaplan-Meier survival 
estimates of the predicting NPC cases from both the training and validation cohorts. 
ROC curves for molecular markers, age at diagnosis, WHO histological classification, 
gender, clinical stage, and the NPC support vector machine (NPC-SVM) classifier as 
predictors of death from NPC within 5 years in the training cohort (A) and the 
validation cohort (B). Kaplan-Meier survival estimates for low-risk and high-risk NPC 
patients as defined by the NPC-SVM classifier. DSS curves of the predicting patients in 
the training cohort (C) and the validation cohort (D. The log-rank test was used to 
calculate p values(Wang et al). 
 
Studies have consistently failed to show that distinguishing between NKDC and NKUC 
NPC subtypes of NPC (98% of NPC in endemic area of Southern China) has any 
clinical relevance (Cho, 2007). However, the NPC-SVM classifier can easily identify 
NPC patients with a good or bad prognosis, and will thus make a valuable complement 
to the WHO classification. The NPC-SVM classifier provides a new strategy and 
approach for optimal clinical decisions. With this prognostic tool, clinicians can 
identify low-risk NPC patients (91% of early-stage and 59% of advanced -stage 
patients), and give them mild treatment to avoid unnecessary radical therapy. In 
contrast, higher-dose radiation, adjuvant therapy, or molecular targeted therapy may 
have additional therapeutic effectiveness in high-risk patients (9% of early-stage, and 
41% of advanced-stage patients). 
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These results should be interpreted in the light of some limitations, including the 
limited number of genes screened in the training cohort, which in turn resulted in a 
smaller panel of genes integrated in the NPC-SVM classifier than in some other gene-
expression-profiling studies by cDNA array in other cancers (Dave et al, 2006; Liu et 
al, 2006; Sanchez-Carbayo et al, 2006). Although the NPC-SVM classifier integrated 
seven informative genes and was a highly accurate predictor of DSS, the inclusion of 
other molecular markers may increase the precision and prognostic value of the 
classifier. In addition, new markers are being found and new techniques developed 
every year. Thus, the NPC-SVM classifier may be further improved by including 
expression data for additional genes. Other limitations of the study included incomplete 
follow-up for some patients and the inclusion of cases predominantly from a single 
clinical center in southeastern China, which may have reduced the validity of 
generalizing from our results. Further prospective studies are therefore needed to 
validate these results, including prospective studies with complete patient follow-up, as 
well as studies in other NPC-endemic areas, such as northern Africa, and in non-
endemic populations. Further studies on high-risk patients are needed to test the 
efficacy of more radical treatments and therapies targeted at the angiogenesis pathway, 
with the potential for opening up a new era of NPC treatment. 
 
In conclusion, the present study demonstrated that IHC- and SVM-based approaches 
can be used to distinguish accurately between NPC patients with substantially different 
clinical outcomes, even after adjustment for clinical stage, histological subtype, and age. 
Thus, the NPC-SVM classifier offers considerable improvement over existing methods 
for the prognostic classification of NPC patients, and has the potential to provide 
clinicians with useful, readily available information for personalizing therapy aimed at 
NPC targets.  
 
New Histopathological Classification of NPC (Manuscript) 
Many classification schemes have been proposed for NPC since the early 20th 
century. The latest classification proposed by the WHO divides NPC into two main 
types:-non-keratinizing carcinoma and KSCC. In practice, however, there is a gradual 
transition between these two histological types and the prognostic significance of the 
subdivision remains unclear. Though that the WHO classification happened to 
correlate pretty well with EBV-positivity, type III being EBV positive and type I 
EBV-negative. NPC is, however, a heterogeneous malignancy, and clinical outcome 
can vary substantially among patients at the same clinical stage. Limitations of the 
WHO classification therefore include unclear boundaries between the categories and 
insufficient prognostic value. 
 
In this multicenter study, we proposed a new histological classification for NPC based 
on tumor cell morphology, cell differentiation, and epithelial-mesenchymal transition 
(EMT) marker expression. We enrolled 3,839 previously untreated patients with 
biopsy-proven NPC from 40 clinical centers, who were treated at nine cancer centers 
between January 1995 and December 2005. According to their morphological features, 
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NPCs could be histologically classified into four subtypes: undifferentiated epithelial 
cell carcinoma (UECC), undifferentiated mixed epithelial- sarcomatoid cell carcinoma 
(UESCC), undifferentiated sarcomatoid cell carcinoma (USCC), and squamous cell 
carcinoma (SCC). Representative features of the novel NPC classification subtypes are 
shown in Figure 11. 
 
Figure 11. Representative morphological features of novel NPC classification subtypes 
(all stained with hematoxylin and eosin (H&E), ×400.) 
 
UECC subtype (Figure 11A–D). This phenotype is characterized by smaller, round 
tumor cells showing cellular stratification and pavementing, often with a lower nuclear-
cytoplasmic ratio, chromatin-rich nuclei, and unprominent nucleoli; or larger, round 
cells, characterized by syncytial-appearing large tumor cells with indistinct cell borders, 
round-to-oval vesicular nuclei, and large central nucleoli; or a vesicular nuclei 
carcinoma phenotype, in which more than 75% of the tumor cells are characterized by a 
round shape with vesicular nuclei and prominent nucleoli.  
 
USCC subtype (Figure 11E–H). More than 50% of the tumor cells in this subtype are 
spindle-shaped, fusiform, or in interlacing bundles (fibrosarcomatous pattern). The 
tumor is composed of irregular small cells, large hyperchromatic cells, or both; or else 
uniformly medium-sized spindle cells. The nucleoli of the spindle cells are often not as 
prominent as in the syncytial-appearing cells. In some cases, tumor cells appear 
shrunken with dark, smudged nuclei and a dense amphophilic or eosinophilic 
cytoplasm. 
 
UESCC subtype (Figure 11I–L). Morphologically, this subtype shows large, round 
cell nests or scattered large, round cell infiltrates in the spindle cell carcinomatous 
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tissue (30–50%). In most cases, no obvious boundaries are seen between the tumor and 
interstitial lymphoid tissue. 
 
SCC subtype (Figure 11M–P). Well-differentiated keratinizing SCC is diagnosed 
when a large number of whorls and keratin are present, and low- and moderately-
differentiated SCC is diagnosed when a number of single-cell, keratinized spine cells 
and a small number of basal-like cells are visualized. 
 
According to the new NPC classification category, of the 3,839 tumors, 2,057 (53.6%) 
were classified histologically as UECC, 942 (24.5%) as UESCC, 640 (16.7%) as USCC, 
and 200 (5.2%) as SCC. The 5-year disease-specific survival (DSS) rates in NPC 
patients differed clinically and significantly among the newly-defined NPC histological 
subtypes, with 5-year DSS rates of 76.4% for UECC, 66.0% for UESCC, 56.0% for 
USCC, and 32.7% for SCC. Thus, the minimum difference in 5-year DSS between 
newly defined histological subtypes was 10%, while a more substantial difference of 
20.4% was detected between UECC and USCC, which together comprised 70% of 
patients in the cohort. Using the WHO classification, the 5-year DSS rates were 69.5% 
for NKUC, 65.5% for NKDC, and 47.8% for KSCC. Thus, 5-year DSS differed by 
only 4% (p = 0.06) between the two WHO histological subtypes that together 
accounted for 98% of patients in the cohort. Using the TNM clinical staging system, 
the 5-year DSS rates were 93.9% for stage I, 86.0% for stage II, 69.7% for stage III, 
and 51.9% for stage IV.  
 
Figure 12. Kaplan-Meier estimates of DSS curves for NPC patients. DSS curves for 
NPC patients according to newly-defined histological subtype (panel A); according to 
WHO subtype (panel B); and according to clinical TNM stage (panel C). 
 
The limitations of the current WHO classification in terms of its clinical application 
include boundaries between the categories that are not always clear, sub-optimal intra- 
and inter-observer reproducibilities, (Shanmugaratnam, 1978; Shanmugaratnam, 1980) 
and insufficient prognostic power (Hsu et al, 1987; Liu & Yeh, 1998; Yu et al, 2005). 
Considerable controversy exists over the available histological NPC classifications and 
their prognostic significance (Baker & Wolfe, 1982; Cellai et al, 1982; Hua et al, 2009; 
Neel et al, 1985; Shanmugaratnam et al, 1979; Zhang et al, 1989). The WHO KSCC 
subtype is identified in one-third to one-half of NPCs in low-risk Western populations, 
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and is reportedly associated with a significantly poorer prognosis than non-keratinzing 
carcinoma (Fu, 1980; Mesic et al, 1981; Neel et al, 1985). However, studies have 
consistently failed to show that the distinction between NKDC and NKUC has any 
clinical relevance. These two subtypes are identified in 98% of NPC in endemic areas 
of China (Yu & Yuan, 2002). In this multicenter study with a large sample size, the 
proposed new histopathological classification of NPC showed significant differences in 
clinical outcomes and survival among the different groups. The UECC NPC subtype 
had the best prognosis, with lower rates of loco-regional recurrence and distant 
metastasis events, and higher 5-year DSS rates. The USCC and UEMC subtypes had 
poorer prognoses, and the SCC NPC subtype showed the worst prognostic outcome, 
similar to the WHO classification. Although the 5-year DSS rates for SCC NPC were 
significantly different from those for non-keratinizing NPC, they were not significantly 
different between the NKDC and NKUC subtypes of WHO classification. After 
stratifying by gender, clinical stage, age, and therapeutic method, the proposed 2010 
NPC classification system retained significant prognostic value. The results provide 
clinicians with an applicable histological classification for better prediction of 
prognosis in NPC patients. To our knowledge, this is the first multicenter, large-sample 
study on the histological classification of NPC. 
 
Our results demonstrated that spindle-shaped NPC tumors (USCC and UESCC) 
showed significant loss of E-cadherin expression and increased expression of the 
mesenchymal markers N-cadherin, CD44v6, Twist, Snail and cyclin D1, suggesting the 
occurrence of an EMT process during the development and progression of NPC; the 
spindle-shaped cells in USCC and UESCC tumors have an EMT phenotype. The 
acquisition of EMT characteristics in USCC and UESCC NPC may give the tumor 
cells a higher invasive potential, as extensive reductions in E-cadherin expression may 
lead to the loss of cell-cell adhesion, resulting in invasive and metastatic behavior. 
Indeed, acquisition of EMT-marker expression and reduction of E-cadherin expression 
in NPC were closely correlated with USCC and UESCC subtypes, local recurrence, 
distant metastasis, and advanced NPC stage. In addition, patients with EMT-marker 
overexpression and loss of E-cadherin expression had significantly poorer prognoses. 
These results regarding EMT events in NPC have been confirmed by recent studies 
(Horikawa et al, 2007; Lin et al, 2009; Song et al, 2009). Combining EMT 
morphological characteristics and EMT-marker expression analysis will provide new 
insights and approaches for improved prediction of recurrence, metastasis, and 
prognosis. Further studies are needed to determine if the results represent EMT or 
merely EMT-like expressional changes, and to identify the mechanism of EMT in NPC 
progression and development.  
 
Although a number of improvements have been achieved in terms of both the 
technology and equipment for RT, treatment outcomes remain disappointing for 
advanced-stage disease treated with RT alone. The landmark Intergroup 00-99 study, as 
well as other studies, demonstrated a clear survival benefit of RCT for patients with 
stage III–IV disease (Baujat et al, 2006). In accordance with the previous trails, our 
retrospective study confirmed the beneficial effect of RCT compared to RT alone in 
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advanced-stage disease. Interestingly, UECC and UESCC subtypes showed 
significantly better survival outcomes with RCT than with RT alone, even after mutual 
adjustment. Meanwhile, the USCC and SCC subtypes showed inferior survival 
outcomes, and RCT treatment had no additional therapeutic gains in this subtype. 
These results indicate that the new histological classification system provides a new 
strategy and approach for optimal clinical decision making. Based on this classification, 
clinicians can avoid using unnecessary radical therapy in low-risk NPC patients 
identified with the UECC subtype (54% of NPC), whereas high-risk NPC patients with 
the USCC (17% of NPC) or SCC subtype (5% of NPC) may be more effectively 
treated with higher-dose radiation, adjuvant therapy, surgical operation, or molecular 
targeted therapy on the EMT markers, which may yield additional therapeutic gains. 
However, data from clinical trials are needed to confirm if different treatment regimens 
are appropriate for the various histological subtypes classified according to our new 
system.  
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Figure 13. Kaplan-Meier estimates of DSS curves stratified by the new classification in 
advanced stage NPC patient. DSS curves of NPC patients according to therapy model 
for NPC patients: UECC subtype (panel A); UESCC subtype (panel B); USCC subtype 
(panel C); and SCC subtype (panel D). 
 
To the best of knowledge, the present study represents the first large, multicenter study 
to propose a new NPC histological classification system that can significantly 
distinguish among NPC subtypes by prognosis and EMT-marker expression levels. 
These results should be further validated by prospective studies with complete patient 
follow-up, as well as studies in other NPC-endemic areas, such as northern Africa, and 
in non-endemic populations. Although the novel NPC classification was correlated with 
EMT markers, we are aware that other molecular evidence may further extend the 
precision and prognostic value of the classification system.  
 
In conclusion, our proposed novel NPC classification system reliably distinguishes 
between prognostically and clinically-distinct groups of NPC patients more effectively 
than the existing WHO classification. This study provided a good opportunity to 
investigate the efficacy of RCT in different subtypes of NPC based on the new 
classification system, and may herald a new era of NPC treatment with improved 
outcomes.    
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CONCLUSIONS 
 
1. Overexpression of Cav-1 leads to CD147 upregulation in NPC, both of which are 
associated with tumor recurrence, metastasis, and poor prognosis. Collectively, 
detection of expression levels of these biomarkers might aid in the stratification of 
NPC, and these biomarkers may represent new potential therapeutic targets in NPC. 
2. LMP1 expression is essential for the activation of the mTOR signaling pathway in 
NPC. LMP1 activates the AKT/mTOR/P70S6K/4EBP1 axis in NPC tumors, and 
high expression levels of LMP1, p-P70S6K and p-4EBP1 predict poor prognosis in 
NPC patients. 
3. Plasma EBV DNA is a more sensitive and specific marker than EBV VCA/IgA 
antibody. Thus, measurement of plasma EBV DNA may be used to enhance 
clinical staging, as well as for early diagnosis, monitoring local recurrence and 
distant metastasis, and predicting prognosis in NPC.  
4. The developed NPC-SVM classifier based on immunomarkers is closely associated 
with overall survival among patients with NPC, and can reliably predict prognosis 
in NPC patients. The results will provide clinicians with useful information for 
personalizing therapy aimed at NPC targets. 
5. The proposed novel NPC histological classification system based on morphological 
features is more accurate than the existing WHO classification for predicting 
prognosis in NPC patients. Further studies on the application of this novel NPC 
classification to identify high-risk patients with USCC and SCC subtypes, and to 
test the efficacy of more radical treatment and therapies targeted at the EMT 
pathway, may open a new era of NPC treatment. 
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SUMMARY AND FUTURE PROSPECTS 
 
With recent advances in genomics, proteomics and bioinformatics in recent decades, 
more understanding of the disease etiology, carcinogenesis and progression has been 
gained in NPC. Despite the crucial role of EBV in NPC, the cellular genes regulated by 
EBV are of particular interest, as they may serve as specific tumor markers and targets 
for novel therapy strategies. Research into the genetic alterations, gene expression, 
EBV and its regulated cellular genes in NPC may unravel the pathways in NPC 
development and potentially decipher the molecular characteristics of the malignancy. 
In the era of molecular medicine, specific treatment to the potential target using 
technologies such as targeted gene therapy, immunotherapy and RNAi becomes 
formulating from bench to bedside application and thus makes molecular biomarker 
discovery more meaningful for NPC management. The molecular biomarker 
discovery and progress in NPC reported in this thesis can be potentially implicated 
with respect to the diagnosis, monitoring, treatment and prognostication of the disease. 
This is summarized and presented in Figure 14. 
Figure 14. Biomarkers screening and their prognostic prediction in NPC 
 
For NPC treatment, major challenges remain in improving the survival rate of 
patients with advanced and recurrent diseases. In this thesis, the newly developed 
NPC-SVM classifier based on tumour associated biomarkers will facilitate patient 
counseling and individualize management of NPC patients. The newly proposed 
novel histological classification will offer more discriminative prediction of NPC 
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prognosis than the current WHO classification and therapeutic efficacy of RCT and 
RT on advanced-stage NPC patients. The two classifications enable the clinician to 
identify high-risk patient, and to give more effective therapeutic approaches may 
brighten up the outcome of NPC patients with poor prognosis. The reclassification of 
NPC and its implication in the personalized treatment of the patients is summarized in 
Figure 15. Ultimately, the mission of clinical researchers is to find the best way of 
applying these new strategies into clinical practice, and in this regard one cannot 
overemphasize the importance of enlisting multicenter or multinational collaboration 
in the validation of promising therapies. 
  
Figure 15. NPC reclassification and its implication in personalized medicine 
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